Blue Trust Inc. Buys 79 Shares of Bio-Rad Laboratories, Inc. $BIO

Blue Trust Inc. lifted its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 5.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,517 shares of the medical research company’s stock after buying an additional 79 shares during the period. Blue Trust Inc.’s holdings in Bio-Rad Laboratories were worth $366,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in BIO. Patriot Financial Group Insurance Agency LLC lifted its position in shares of Bio-Rad Laboratories by 25.9% in the 2nd quarter. Patriot Financial Group Insurance Agency LLC now owns 1,441 shares of the medical research company’s stock worth $348,000 after acquiring an additional 296 shares during the period. RK Asset Management LLC lifted its position in Bio-Rad Laboratories by 0.8% in the second quarter. RK Asset Management LLC now owns 14,502 shares of the medical research company’s stock worth $3,501,000 after purchasing an additional 113 shares during the period. Public Employees Retirement System of Ohio lifted its position in Bio-Rad Laboratories by 3.6% in the second quarter. Public Employees Retirement System of Ohio now owns 6,307 shares of the medical research company’s stock worth $1,522,000 after purchasing an additional 218 shares during the period. GAMMA Investing LLC lifted its position in Bio-Rad Laboratories by 20.9% in the second quarter. GAMMA Investing LLC now owns 734 shares of the medical research company’s stock worth $177,000 after purchasing an additional 127 shares during the period. Finally, UMB Bank n.a. lifted its position in Bio-Rad Laboratories by 89.8% in the second quarter. UMB Bank n.a. now owns 167 shares of the medical research company’s stock worth $40,000 after purchasing an additional 79 shares during the period. Institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Stock Performance

NYSE:BIO opened at $303.56 on Tuesday. Bio-Rad Laboratories, Inc. has a 1 year low of $211.43 and a 1 year high of $387.99. The firm has a 50 day moving average of $286.62 and a 200-day moving average of $256.93. The company has a current ratio of 5.12, a quick ratio of 3.67 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $8.21 billion, a P/E ratio of 25.88 and a beta of 0.97.

Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Thursday, July 31st. The medical research company reported $2.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.93 by $0.68. Bio-Rad Laboratories had a net margin of 12.50% and a return on equity of 4.01%. The company had revenue of $651.60 million during the quarter, compared to analysts’ expectations of $614.82 million. During the same quarter in the previous year, the company posted $3.11 earnings per share. Bio-Rad Laboratories’s quarterly revenue was up 2.1% compared to the same quarter last year. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently commented on BIO. Wells Fargo & Company raised their price objective on shares of Bio-Rad Laboratories from $245.00 to $265.00 and gave the stock an “equal weight” rating in a report on Friday, August 1st. Weiss Ratings restated a “sell (d)” rating on shares of Bio-Rad Laboratories in a research note on Saturday, September 27th. Zacks Research upgraded shares of Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 26th. Wall Street Zen downgraded Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, August 22nd. Finally, Royal Bank Of Canada raised their target price on Bio-Rad Laboratories from $387.00 to $409.00 and gave the stock an “outperform” rating in a research report on Friday, August 1st. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $333.50.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.